-
Posted by
Two Blokes Jun 30 -
Filed in
Stock
-
6 views
In the Phase 2 MINDFuL trial of XPro\u2122 in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a predefined population of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100), a benefit of XPro\u2122 treatment over placebo was observed in cognitive, behavioral and biological endpoints.
